U.S. Food and Drug Administration (FDA) PDUFA goal date for ONS-5010 is August 27, 2025. Off-label repackaged bevacizumab is one of the most frequently used first-line anti-VEGF treatments in Europe ...
GE Vernova raises multi-year financial outlook, doubles dividend and increases buyback authorization
NEW YORK--(BUSINESS WIRE)-- GE Vernova (GEV), a unique industry leader enabling customers to accelerate the energy transition, today hosts its 2025 Investor Update event to present its 2026 financial ...
WASHINGTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The U.S. economy is expected to remain resilient in 2026 despite a moderation in growth, according to the 2026 Equipment Leasing & Finance U.S. Economic ...
Vanguard has released its annual outlook on the global economy and financial markets. This year’s report, “AI exuberance: Economic upside, stock market downside,” provides investors with an economic ...
ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results